Kalvista Pharmaceuticals Stock Analysis

Kalvista Stock Analysis Notes

About 99.0% of the company shares are owned by institutional investors. The book value of Kalvista Pharmaceuticals was now reported as 4.86. The company recorded a loss per share of 3.68. Kalvista Pharmaceuticals last dividend was issued on the 22nd of November 2016. The entity had 1:14 split on the 22nd of November 2016. KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks KVD824, an oral product candidate for the treatment of HAE and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. Kalvista Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people. To find out more about Kalvista Pharmaceuticals contact Thomas MBA at 857 999 0075 or learn more at https://www.kalvista.com.

Kalvista Pharmaceuticals Investment Alerts

Kalvista Pharmaceuticals Upcoming and Recent Events

Kalvista Largest EPS Surprises

View All Earnings Estimates

Kalvista Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Kalvista Stock Institutional Investors

Note, although Kalvista Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Kalvista Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 433.4 M.

Kalvista Profitablity

Management Efficiency

Kalvista Pharmaceuticals has return on total asset (ROA) of (0.5394) % which means that it has lost $0.5394 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9084) %, meaning that it created substantial loss on money invested by shareholders. Kalvista Pharmaceuticals' management efficiency ratios could be used to measure how well Kalvista Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Kalvista Pharmaceuticals' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 0.17 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (1.03). At this time, Kalvista Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 11.7 M in 2025, despite the fact that Return On Tangible Assets are likely to grow to (1.03).

Technical Drivers

As of the 31st of January, Kalvista Pharmaceuticals secures the Standard Deviation of 3.79, risk adjusted performance of (0.08), and Mean Deviation of 3.05. Kalvista Pharmaceuticals technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Please verify Kalvista Pharmaceuticals variance and potential upside to decide if Kalvista Pharmaceuticals is priced some-what accurately, providing market reflects its recent price of 8.77 per share. Given that Kalvista Pharmaceuticals has information ratio of (0.14), we recommend you to check Kalvista Pharmaceuticals's last-minute market performance to make sure the company can sustain itself at a future point.

Kalvista Pharmaceuticals Price Movement Analysis

Kalvista Pharmaceuticals Insider Trading Activities

Kalvista Pharmaceuticals Outstanding Bonds

Kalvista Pharmaceuticals Predictive Daily Indicators

Kalvista Pharmaceuticals Corporate Filings

Kalvista Pharmaceuticals Forecast Models

Kalvista Pharmaceuticals' time-series forecasting models are one of many Kalvista Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Kalvista Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Kalvista Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Kalvista shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Kalvista Pharmaceuticals. By using and applying Kalvista Stock analysis, traders can create a robust methodology for identifying Kalvista entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Kalvista analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Kalvista analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Kalvista Pharmaceuticals stock analysis indicators help investors evaluate how Kalvista Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Kalvista Pharmaceuticals shares will generate the highest return on investment. By understating and applying Kalvista Pharmaceuticals stock analysis, traders can identify Kalvista Pharmaceuticals position entry and exit signals to maximize returns.

When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.